RT Journal Article
SR Electronic
T1 GRAPPA Treatment Recommendations: 2021 Update
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 52
OP 54
DO 10.3899/jrheum.211331
VO 49
IS 6 Suppl 1
A1 Laura C. Coates
A1 Nadia Corp
A1 Danielle A. van der Windt
A1 Denis O’Sullivan
A1 Enrique R. Soriano
A1 Arthur Kavanaugh
YR 2022
UL http://www.jrheum.org/content/49/6_Suppl_1/52.abstract
AB Since its inception, one of the central missions of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been the development of treatment recommendations for patients with psoriatic arthritis (PsA). The initial guidelines, developed in 2009, were updated in 2015. Because of the abundance of new data concerning the therapeutic approach to PsA, GRAPPA members have been working throughout 2020–2021 to once again update the recommendations. At the GRAPPA 2021 annual meeting, the full committee presented proposals from each of the treatment domain groups, including the comorbidities and related conditions groups, based on previous systematic literature reviews. Overarching principles and summary evidence tables were presented, including results from a GRAPPA membership survey of patients and clinicians to assess levels of agreement. A draft of the figure for the treatment recommendations was presented and discussed with the wider membership.